

## Supporting Information

# Regioselective Alkylation of Carbohydrates and Diols: A Cheaper Iron Catalyst, New Applications and Mechanism

*Bo Ren\*, Ningning Yan and Lu Gan*

College of Chemistry & Chemical Engineering, Xinyang Normal University, Nanhu  
Road 237, Xinyang, Henan, 464000, P. R. China

[renbo@xynu.edu.cn](mailto:renbo@xynu.edu.cn)

**General:** All commercially available starting materials and solvents were of reagent grade and used without further purification. Chemical reactions were monitored with thin-layer chromatography using precoated silica gel 60 (0.25 mm thickness) plates. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded using a Bruker Avance 400 instrument or a Bruker DMX 500 instrument at 298K in CDCl<sub>3</sub>, using the residual signals from CHCl<sub>3</sub> (<sup>1</sup>H: δ = 7.25 ppm; <sup>13</sup>C: δ = 77.2 ppm) as the internal standard. <sup>1</sup>H NMR peak assignments were made by first-order analysis of the spectra, supported by standard <sup>1</sup>H-<sup>1</sup>H NMR correlation spectroscopy (COSY).

**General method for regioselective alkylation of diols and polyols:**

1. The substrates (50 mg) were allowed to react with RX (alkylation reagents) (1.1 eq.) in dry acetonitrile (1 mL) or a mixed solvent (MeCN/DMF: 10/1) at 40 °C for 2 - 3 h in the presence of Ag<sub>2</sub>O (0.6 eq.), TBAB (0.1 eq.) and Fe(dipm)<sub>3</sub> (0.1 eq.). The reaction mixtures were filtered and directly purified by flash column chromatography (hexanes/EtOAc = 3:1 to 1:1) to afford the pure products.
2. Diol and polyol reactants (50 mg) were allowed to react with RX (alkylation reagents) (1.1eq.) in 1 mL of dry acetonitrile at 80 °C for 8 h, in the presence of Fe(dipm)<sub>3</sub> (0.1 eq.) and K<sub>2</sub>CO<sub>3</sub> (1.5 eq.). After cooling and evaporating the solvent, the reaction mixture was directly purified by flash column chromatography (hexanes–EtOAc 3:1 to 1:1), affording the pure products.

Spectroscopic data of the known products were in accordance with those reported in the literature.

**Methyl 3-*O*-(4-methoxybenzyl)-4,6-*O*-benzylidene- $\alpha$ -D-mannopyranoside (5).** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.62 – 7.18 (m, 7H, PhCH, MeO-PhCH<sub>2</sub>), 6.85 (d, *J* = 8.6 Hz, 2H, MeO-PhCH<sub>2</sub>), 5.60 (s, 1H, PhCH), 4.77 (d, *J* = 11.4 Hz, 1H, MeO-PhCH<sub>2</sub>), 4.72(s, 1H, H-1), 4.62 (d, *J* = 11.4 Hz, 1H, MeO-PhCH<sub>2</sub>), 4.27 (dd, *J*<sub>1</sub> = 3.9 Hz, *J*<sub>2</sub> = 9.6 Hz, 1H, H-4), 4.07 (dd, *J*<sub>1</sub> = 7.1 Hz, *J*<sub>2</sub> = 14.3 Hz, 1H, H-6<sub>a</sub>), 3.96 (s, 1H, H-2), 3.91–3.75 (m, 6H, H-3, H-5, H-6<sub>b</sub>, MeO-PhCH<sub>2</sub>), 3.36 (s, 3H, OMe), 2.83 (s,

1H, 2-OH) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  159.5, 137.7, 130.2, 129.7, 129.0, 128.3, 126.2, 113.9, 101.7, 101.2, 78.9, 75.4, 72.8, 69.9, 69.0, 63.3, 55.4, 55.0 ppm.

**Methyl 3-*O*-(4-bromobenzyl)-4,6-*O*-benzylidene- $\alpha$ -D-mannopyranoside (6).**  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.55–7.32 (m, 7H, PhCH, Br-PhCH<sub>2</sub>), 7.21 (d,  $J$  = 8.3 Hz, 2H, Br-PhCH<sub>2</sub>), 5.59 (s, 1H, PhCH), 4.82–4.70 (m, 2H, Br-PhCH<sub>2</sub>, H-1), 4.66 (d,  $J$  = 12.2 Hz, 1H, Br-PhCH<sub>2</sub>), 4.27 (dd,  $J_1$  = 4.1 Hz,  $J_2$  = 9.6 Hz, 1H, H-4), 4.08 (dd,  $J_1$  = 7.1 Hz,  $J_2$  = 14.3 Hz, 1H, H-6<sub>a</sub>), 4.01 (s, 1H, H-2), 3.94–3.72 (m, 3H, H-3, H-5, H-6<sub>b</sub>), 3.37 (s, 3H, OMe), 2.73 (s, 1H, 2-OH) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  137.6, 137.1, 131.7, 129.6, 129.1, 128.4, 126.2, 121.9, 101.8, 101.2, 78.9, 75.7, 72.3, 70.0, 69.0, 63.3, 55.1 ppm.

**Methyl 3-*O*-allyl-4,6-*O*-benzylidene- $\alpha$ -D-mannopyranoside (7).**  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.49 (d,  $J$  = 7.7 Hz, 2H, PhCH), 7.44–7.30 (m, 3H, PhCH), 5.83–5.61 (m, 1H, CH<sub>2</sub>CH=CH<sub>2</sub>), 5.59 (s, 1H, PhCH), 5.37–5.25 (m, 2H, CH<sub>2</sub>CH=CH<sub>2</sub>), 5.19 (d,  $J$  = 10.4 Hz, 1H, CH<sub>2</sub>CH=CH<sub>2</sub>), 4.78 (s, 1H, H-1), 4.39–4.23 (m, 2H, CH<sub>2</sub>CH=CH<sub>2</sub>, H-4), 4.20 (dd,  $J_1$  = 5.9 Hz,  $J_2$  = 12.8 Hz, 1H, CH<sub>2</sub>CH=CH<sub>2</sub>), 4.12–4.00 (m, 2H, H-2, H-6<sub>a</sub>), 3.91–3.75 (m, 3H, H-3, H-5, H-6<sub>b</sub>), 3.39 (s, 3H, OMe), 2.77 (s, 1H, 2-OH) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  137.7, 134.6, 129.0, 128.3, 126.2, 117.6, 101.7, 101.2, 78.9, 75.3, 72.0, 70.0, 69.0, 63.3, 55.1 ppm.

**Methyl 3-*O*-(2-cyanobenzyl)-4,6-*O*-benzylidene- $\alpha$ -D-mannopyranoside (8).**  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.61 (d,  $J$  = 7.6 Hz, 1H, PhCH), 7.56–7.46 (m, 4H, CN-PhCH<sub>2</sub>), 7.41–7.33 (m, 4H, PhCH), 5.61 (s, 1H, PhCH), 4.98 (d,  $J$  = 12.4 Hz, 1H, CN-PhCH<sub>2</sub>), 4.92 (d,  $J$  = 12.4 Hz, 1H, CN-PhCH<sub>2</sub>), 4.78 (s, 1H, H-1), 4.29 (dd,  $J_1$  = 4.3 Hz,  $J_2$  = 9.8 Hz, 1H, H-4), 4.23–4.13 (m, 2H, H-2, H-6<sub>a</sub>), 3.97–3.77 (m, 3H, H-3, H-5, H-6<sub>b</sub>), 3.39 (s, 3H, OMe), 2.90 (s, 1H, 2-OH) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  141.6, 137.6, 133.1, 132.9, 129.1, 128.3, 126.2, 117.8, 111.7, 101.7, 101.3, 78.8, 76.6, 71.0, 69.8, 69.0, 63.4, 55.1.

**Methyl 3-O-allyl-6-O-(*tert*-butyldimethylsilyloxy)- $\alpha$ -D-mannopyranoside (10).**  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  6.10–5.88 (m, 1H,  $\text{CH}_2\text{CH}=\text{CH}_2$ ), 5.32 (dd,  $J_1 = 17.2$ ,  $J_2 = 1.5$  Hz, 1H,  $\text{CH}_2\text{CH}=\text{CH}_2$ ), 5.22 (dd,  $J_1 = 10.4$ ,  $J_2 = 1.1$  Hz, 1H,  $\text{CH}_2\text{CH}=\text{CH}_2$ ), 4.74 (s, 1H, H-1), 4.23–4.11 (m, 2H,  $\text{CH}_2\text{CH}=\text{CH}_2$ ), 3.97 (s, 1H, H-2), 3.93–3.79 (m, 3H, H-4, H-6<sub>a</sub>, H-6<sub>b</sub>), 3.67–3.52 (m, 2H, H-3, H-5), 3.37 (s, 3H, OMe), 3.06 (s, 1H, 4-OH), 2.42 (s, 1H, 2-OH), 0.90 (s, 9H, Si(CH<sub>3</sub>)<sub>3</sub>), 0.09 (s, 6H, Si(CH<sub>3</sub>)<sub>2</sub>) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  134.6, 118.0, 100.5, 79.0, 71.0, 70.8, 69.4, 67.9, 65.0, 55.0, 26.0, 18.4, -5.4 ppm.

**Table S1** Comparison the isolation yields of alkylolation methods using catalytic amounts of  $\text{Fe}(\text{dibm})_3$  and  $\text{Fe}(\text{dipm})_3$ .

| Entry | Substrate | Major product | Yields                         |                                |
|-------|-----------|---------------|--------------------------------|--------------------------------|
|       |           |               | ( $\text{Fe}(\text{dibm})_3$ ) | ( $\text{Fe}(\text{dipm})_3$ ) |
| 1     |           |               | 96%                            | 93%                            |
| 2     |           |               | 96%                            | 98%                            |
| 3     |           |               | 98%                            | 94%                            |
| 4     |           |               | 98%                            | 94%                            |
| 5     |           |               | 97%                            | 85%                            |
| 6     |           |               | 89%                            | 91%                            |
| 7     |           |               | 91%                            | 91%                            |
| 8     |           |               | 75%                            | 92%                            |
| 9     |           |               | 87%                            | 91%                            |
| 10    |           |               | 89%                            | 94%                            |


|    |  |  |     |     |
|----|--|--|-----|-----|
| 11 |  |  | 86% | 80% |
| 12 |  |  | 83% | 85% |
| 13 |  |  | 90% | 90% |
| 15 |  |  | 98% | 78% |
| 16 |  |  | 91% | 86% |
| 17 |  |  | 94% | 93% |
| 18 |  |  | 75% | 75% |
| 19 |  |  | 80% | 86% |
| 20 |  |  | 86% | 90% |
| 21 |  |  | 58% | 64% |

**Figure S1** Recrystallized Fe(dipm)<sub>3</sub>.




**Figure S2**

<sup>1</sup>H-NMR of 2,6-dimethyl-4-benzyl-3,5- heptadione (The product of BnBr and dibm)




**Methyl 3-*O*-benzyl-4, 6-*O*-benzylidene- $\alpha$ -D-mannopyranoside (2)<sup>1</sup>:**


<sup>1</sup>H-NMR of compound 2 (CDCl<sub>3</sub>)




**Methyl 3-*O*-benzyl-6-*O*-(*tert*-butyldimethylsilyloxy)- $\alpha$ -D-mannopyranoside (4)<sup>2</sup>:**  
<sup>1</sup>H-NMR of compound 4 (CDCl<sub>3</sub>)




**Methyl 3-*O*-(4-methoxybenzyl)-4, 6-*O*-benzylidene- $\alpha$ -D-mannopyranoside (5)<sup>3</sup>:**  
<sup>1</sup>H-NMR of compound 5 (CDCl<sub>3</sub>)




<sup>13</sup>C-NMR of compound **5** ( $\text{CDCl}_3$ )



**Methyl 3-*O*-(4-bromobenzyl)-4, 6-*O*-benzylidene- $\alpha$ -D-mannopyranoside (**6**)<sup>3</sup>:**  
<sup>1</sup>H-NMR of compound **6** ( $\text{CDCl}_3$ )




<sup>13</sup>C-NMR of compound **6** ( $\text{CDCl}_3$ )




**Methyl 3-*O*-allyl-4, 6-*O*-benzylidene- $\alpha$ -D-mannopyranoside (7)<sup>3</sup>:**

<sup>1</sup>H-NMR of compound **7** ( $\text{CDCl}_3$ )




<sup>13</sup>C-NMR of compound **7** ( $\text{CDCl}_3$ )




### Methyl 3-*O*-(2-cyanobenzyl)-4, 6-*O*-benzylidene- $\alpha$ -D-mannopyranoside (8)<sup>3</sup>:

<sup>1</sup>H-NMR of compound **8** ( $\text{CDCl}_3$ )




<sup>13</sup>C-NMR of compound **8** (CDCl<sub>3</sub>)




**Methyl 3-*O*-(4-bromobenzyl)-6-*O*-(*tert*-butyldimethylsilyloxy)- $\alpha$ -D-mannopyranoside (**9**)<sup>4</sup>:**


<sup>1</sup>H-NMR of compound **9** (CDCl<sub>3</sub>)




**Methyl 3-*O*-allyl-6-*O*-(*tert*-butyldimethylsilyloxy)- $\alpha$ -D-mannopyranoside (**10**)<sup>3</sup>:**  
<sup>1</sup>H-NMR of compound **10** (CDCl<sub>3</sub>)




<sup>13</sup>C-NMR of compound **10** (CDCl<sub>3</sub>)



**Methyl 3-O-benzyl-6-O-(*tert*-butyldimethylsilyloxy)- $\beta$ -D-galactopyranoside (12)<sup>4</sup>:**  
<sup>1</sup>H-NMR of compound 12 (CDCl<sub>3</sub>)




**Methyl 3-O-benzyl-6-O-(*tert*-butyldimethylsilyloxy)- $\alpha$ -D-galactopyranoside (14)<sup>4</sup>:**  
<sup>1</sup>H-NMR of compound 14 (CDCl<sub>3</sub>)




**Methyl 2, 3, 6-tri-*O*-benzyl- $\beta$ -D-galactopyranoside (16)<sup>5</sup>:**

<sup>1</sup>H-NMR of compound 16 (CDCl<sub>3</sub>)




**Methyl 3-*O*-benzyl- $\alpha$ -D-mannopyranoside (18)<sup>1</sup>:**

<sup>1</sup>H-NMR of compound 18 (CDCl<sub>3</sub>)




### Methyl 3-*O*-benzyl- $\beta$ -D-galactopyranoside (20)<sup>1</sup>:

<sup>1</sup>H-NMR of compound **20** ( $\text{CDCl}_3$ )




### **Methyl 3-*O*-benzyl- $\alpha$ -D-galactopyranoside (22)<sup>1</sup>:**

<sup>1</sup>H-NMR of compound **22** ( $\text{CDCl}_3$ )




#### Methyl 2, 3, 6-tri-O-benzyl- $\alpha$ -D-glucopyranoside (26)<sup>6</sup>:

<sup>1</sup>H-NMR of compound **26** ( $\text{CDCl}_3$ )




### **2-O-benzyl-1-Phenylethane-1, 2-diol (29)<sup>1</sup>:**

<sup>1</sup>H-NMR of compound **29** ( $\text{CDCl}_3$ )




**1-O-benzyl-1, 2-Propanediol (31)<sup>1</sup>:**

<sup>1</sup>H-NMR of compound 31 (CDCl<sub>3</sub>)




**1-O-benzyl-1, 3-Butanediol (33)<sup>7</sup>:**

<sup>1</sup>H-NMR of compound 33 (CDCl<sub>3</sub>)



**1-O-benzyl-1,3-propanediol (35)<sup>8</sup>:**

<sup>1</sup>H-NMR of compound 35 (CDCl<sub>3</sub>)



## Reference

1. Xu, H.; Lu, Y.; Zhou, Y.; Ren, B.; Pei, Y.; Dong, H.; Pei, Z. *Adv. Synth. Catal.* **2014**, *356*, 1735.
2. Yang, G.; Kong, F.; Zhou, S. *Carbohydr. Res.* **1991**, *211*, 179.
3. Ren, B.; Ramstrom, O.; Zhang, Q.; Ge, J.; Dong, H. *Chem. Eur. J.* **2016**, *22*, 2481.
4. Chan, L.; Taylor, M. S. *Org. Lett.* **2011**, *13*, 3090.
5. Sakagami, M.; Hamana, H. *Tetrahedron Lett.* **2000**, *41*, 5547.
6. Eby, R.; Ehstlra, K.; Schuerch, C. *Carbohydr. Res.*, **1984**, *129*, 111.
7. Lee, D.; Williamson, C. L.; Chan, L.; Taylor, M. S. *J. Am. Chem. Soc.* **2012**, *134*, 8260.
8. Zhou, X. T.; Carter, R. G. *Chem. Commun.* **2004**, *19*, 2138.